On October 19, 2023 Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, reported that a late-breaking abstract featuring data for the company’s NeXT Personal whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, on October 21 in Madrid, Spain (Press release, Personalis, OCT 19, 2023, View Source [SID1234636163]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation #LBA55
Title: "An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer"
Location: Salamanca Auditorium – Hall 3
Date: October 21, 2023
Time: 10:15 – 10:25 CEST
Presenter: Dr. James R. Black MD, PhD, Francis Crick Institute
Late-breaking abstracts are typically reserved for high-quality, new research findings from randomized phase II or phase III trials with implications for clinical practice or understanding of disease processes. Proffered papers are oral presentations of original data of superior quality, followed by expert discussion and perspectives.